Amneal制药 AMRX 深 沪
已收盘 02-06 16:00:00 美东时间
14.52
-0.250
-1.69%
华盛通- 最 高14.985
- 今 开14.89
- 成交量 319.14万股
- 最 低 14.49
- 昨 收 14.77
- 总市值 45.65亿
- 52周最高 15.00
- 市盈率 静 --
- 换手率 1.02%
- 52周最低 6.685
- 委 比 94.77%
- 总股本 3.14亿
- 历史最高 24.48
- 量 比 1.12
- 振 幅 3.35%
- 历史最低 1.24
- 每 手 1
- 风险率 2.04%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Amneal Pharmaceuticals senkt Zinsmarge bei bestehendem Terminkredit um 50 Basispunkte
Amneal Pharmaceuticals senkt Zinsmarge bei bestehendem Terminkredit um 50 Basispunkte Amneal Pharmaceuticals Inc. hat über seine Tochtergesellschaft Amneal Pharmaceuticals LLC eine Änderung der bestehenden Unternehmensfinanzierungsvereinbarung mit JPMorgan Chase Bank und weiteren Kreditgebern abgesc
02-03 19:02
Amneal Pharmaceuticals Cuts Loan Interest Rate in $2.1 Billion Credit Agreement Amendment
Amneal Pharmaceuticals Cuts Loan Interest Rate in $2.1 Billion Credit Agreement Amendment Amneal Pharmaceuticals Inc. has announced that its subsidiary, Amneal Pharmaceuticals LLC, along with certain guarantor subsidiaries, entered into Amendment No. 2 to its Term Loan Credit Agreement with JPMorgan
02-03 19:02
Amneal initiates nationwide settlement for opioid-related claims
Amneal Pharmaceuticals (AMRX) disclosed that its previously announced agreement to settle a majority of opioid-related claims against the company will take effect on Thursday, allowing claimants to re...
01-30 00:23
Amneal Finalizes Nationwide Opioid Settlement Implementation Plan
Amneal Pharmaceuticals ( ($AMRX) ) has provided an announcement. On January 23,...
01-29 05:56
BRIEF-Amneal Pharma To Settle Majority Of Opioids-Related Claims
BRIEF-Amneal Pharma To Settle Majority Of Opioids-Related Claims Jan 28 (Reuters) - Amneal Pharmaceuticals Inc AMRX.O : AMNEAL PHARMA - TO SETTLE MAJORITY OF OPIOIDS-RELATED CLAIMS - SEC FILING AMNEAL PHARMA - OPIOIDS SETTLEMENT AGREEMENT EFFECTIVE JANUARY 29, 2026 - SEC FILING AMNEAL PHARMA - TO PA
01-29 05:26
BUZZ-U.S. STOCKS ON THE MOVE-Amneal Pharma, Ardelyx, Snap
BUZZ-U.S. STOCKS ON THE MOVE-Amneal Pharma, Ardelyx, Snap Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The S&P 500 crossed the 7,000 mark for the first time on Wednesday and the N
01-28 23:48
Amneal Pharmaceuticals Added to S&P SmallCap 600® Index
Amneal Pharmaceuticals has been added to the S&P SmallCap 600 Index, effective January 30, 2026. This reflects the company’s strong performance and aligns with the index’s criteria for financial stability and investor appeal. The inclusion is expected to enhance Amneal’s visibility and attract a broader investor base.
01-28 21:05
Amneal to Report Fourth Quarter and Full Year 2025 Results on February 27, 2026
Amneal Pharmaceuticals announced that it will release its fourth quarter and full year 2025 financial results on February 27, 2026, alongside hosting an 8:30 a.m. ET audio webcast. Details and access information can be found on its Investor Relations website. The company, based in Bridgewater, NJ, operates in pharmaceutical development and distribution across segments including affordable medicines, specialty pharmaceuticals, and government distr...
01-27 13:00
Amneal Pharmaceuticals Files Routine Regulation FD Disclosure Report
An announcement from Amneal Pharmaceuticals ( ($AMRX) ) is now available. On Ja...
01-13 21:18
Amneal Pharmaceuticals Affirms FY2025 Adj EPS Guidance of $0.75-$0.80 vs $0.80 Est; Affirms FY2025 Sales Guidance of $3.000B-$3.100B vs $3.012B Est
Amneal Pharmaceuticals (NASDAQ:AMRX) affirms FY2025 Adj EPS guidance from $0.75-$0.80 to $0.75-$0.80 vs $0.80 analyst estimate. Affirms FY2025 sales outlook from $3.000 billion-$3.100 billion to $3.000 billion-$3.100
01-13 20:50
